AGILENT TECHNOLOGIES, INC.
Business
AGILENT TECHNOLOGIES, INC. provides application‑focused solutions for life sciences, diagnostics and applied markets, delivering instruments, software, services and consumables that support laboratory workflows. Its main offerings include liquid chromatography and mass spectrometry systems, pathology and cell analysis platforms, genomics reagents and companion diagnostics, biomolecular analysis tools, CDMO services for oligonucleotide APIs, laboratory automation, software/informatics, and a broad consumables and service portfolio. The company operates three reportable segments: Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. It sells primarily through direct sales supported by distributors, resellers, representatives and e‑commerce across global markets.
Summary from filing dated 2025-12-22
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-10-31 | FY 2024 2024-10-31 | FY 2023 2023-10-31 | FY 2022 2022-10-31 | FY 2021 2021-10-31 |
|---|---|---|---|---|---|---|
| Net revenue | 6,948 | 6,510 | 6,833 | 6,848 | 6,319 | |
| Cost of revenue | 3,305 | 2,975 | 3,368 | 3,126 | 2,912 | |
| Research and development | 455 | 479 | 481 | 467 | 441 | |
| Selling, general and administrative | 1,709 | 1,568 | 1,634 | 1,637 | 1,619 | |
| Total costs and expenses | 5,469 | 5,022 | 5,483 | 5,230 | 4,972 | |
| Income from operations | 1,479 | 1,488 | 1,350 | 1,618 | 1,347 | |
| Interest income | 62 | 80 | 51 | 9 | 2 | |
| Interest expense | −112 | −96 | −95 | −84 | −81 | |
| Other income (expense), net | 6 | 49 | 33 | −39 | 92 | |
| Income before taxes, as reported | 1,435 | 1,521 | 1,339 | 1,504 | 1,360 | |
| Provision for income taxes | 132 | 232 | 99 | 250 | 150 | |
| Net Income | 1,303 | 1,289 | 1,240 | 1,254 | 1,210 | |
| Net income per share - basic | 4.59 | 4.44 | 4.22 | 4.19 | 3.98 | |
| Net income per share - diluted | 4.57 | 4.43 | 4.19 | 4.18 | 3.94 | |
| Basic (in shares) | 284 | 290 | 294 | 299 | 304 | |
| Diluted (in shares) | 285 | 291 | 296 | 300 | 307 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-10-31 | FY 2024 2024-10-31 | FY 2023 2023-10-31 | FY 2022 2022-10-31 | FY 2021 2021-10-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 1,789 | 1,329 | 1,590 | 1,053 | 1,484 | |
| Accounts receivable, net | 1,487 | 1,324 | 1,291 | 1,405 | 1,172 | |
| Inventory | 1,025 | 972 | 1,031 | 1,038 | 830 | |
| Other current assets | 293 | 334 | 274 | 282 | 222 | |
| Total current assets | 4,594 | 3,959 | 4,186 | 3,778 | 3,799 | |
| Property, plant and equipment, net | 2,023 | 1,778 | 1,270 | 1,100 | 945 | |
| Goodwill | 4,473 | 4,477 | 3,960 | 3,952 | 3,975 | |
| Other intangible assets, net | 445 | 547 | 475 | 821 | 981 | |
| Long-term investments | 133 | 175 | 164 | 195 | 185 | |
| Other assets | 1,059 | 910 | 708 | 686 | 820 | |
| Total assets | 12,727 | 11,846 | 10,763 | 10,532 | 10,705 | |
| Accounts payable | 570 | 540 | 418 | 580 | 446 | |
| Employee compensation and benefits | 443 | 368 | 371 | 455 | 493 | |
| Deferred revenue | 624 | 544 | 505 | 461 | 441 | |
| Short-term debt | 304 | 45 | 0 | 36 | 0 | |
| Other accrued liabilities | 406 | 398 | 309 | 329 | 328 | |
| Total current liabilities | 2,347 | 1,895 | 1,603 | 1,861 | 1,708 | |
| Long-Term Debt | 3,050 | 3,345 | 2,735 | 2,733 | 2,729 | |
| Retirement and post-retirement benefits | 126 | 130 | 103 | 97 | 220 | |
| Other long-term liabilities | 463 | 578 | 477 | 536 | 659 | |
| Total liabilities | 5,986 | 5,948 | 4,918 | 5,227 | 5,316 | |
| Commitments and contingencies (Note 18) | — | — | — | — | — | |
| Preferred stock; $0.01 par value; 125,000,000 shares authorized; none issued and outstanding | 0 | 0 | 0 | 0 | 0 | |
| Common stock; $0.01 par value; 2,000,000,000 shares authorized; 283,054,377 shares at October 31, 2025 and 285,193,011 shares at October 31, 2024 issued and outstanding | 3 | 3 | 3 | 3 | 3 | |
| Additional paid-in-capital | 5,575 | 5,450 | 5,387 | 5,325 | 5,320 | |
| Retained earnings | 1,389 | 750 | 782 | 324 | 348 | |
| Accumulated other comprehensive loss | −226 | −305 | −327 | −347 | −282 | |
| Total stockholders' equity | 6,741 | 5,898 | 5,845 | 5,305 | 5,389 | |
| Total liabilities and stockholders' equity | 12,727 | 11,846 | 10,763 | 10,532 | 10,705 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-10-31 | FY 2024 2024-10-31 | FY 2023 2023-10-31 | FY 2022 2022-10-31 | FY 2021 2021-10-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 288 | 257 | 271 | 317 | 321 | |
| Share-based compensation | 128 | 129 | 111 | 125 | 110 | |
| Deferred taxes expense (benefit) | −130 | −64 | −56 | 8 | 14 | |
| Excess and obsolete inventory related charges | 45 | 45 | 40 | 24 | 29 | |
| Net gain (loss) on equity securities | −36 | 6 | −41 | −67 | 98 | |
| Asset impairment charges | 15 | 19 | 277 | 0 | 2 | |
| Change in fair value of contingent consideration | 0 | 0 | 1 | −25 | −21 | |
| Net gain on Divestiture of Business | 0 | 0 | 43 | 0 | 0 | |
| Other non-cash expense, net | 5 | −1 | 6 | 11 | 3 | |
| Accounts receivable, net | −149 | 7 | 132 | −321 | −128 | |
| Inventory | −97 | 34 | −33 | −248 | −136 | |
| Accounts payable | 16 | 103 | −171 | 121 | 64 | |
| Employee compensation and benefits | 69 | −12 | −91 | −22 | 112 | |
| Other assets and liabilities | 30 | −49 | 47 | −8 | −14 | |
| Net cash provided by operating activities | 1,559 | 1,751 | 1,772 | 1,312 | 1,485 | |
| Payments to acquire property, plant and equipment | −407 | −378 | −298 | −291 | −188 | |
| Proceeds from the sale of equity securities | 8 | 0 | 5 | 22 | 12 | |
| Payments to acquire equity securities | 0 | −5 | −8 | −13 | −22 | |
| Proceeds from convertible note | 2 | 0 | 4 | 0 | 0 | |
| Payment in exchange for convertible note | −1 | −13 | −12 | −4 | −5 | |
| Proceeds from Divestiture of Businesses | 0 | 0 | 50 | 0 | 0 | |
| Acquisitions of businesses and intangible assets, net of cash acquired | 4 | −862 | −51 | −52 | −547 | |
| Net cash used in investing activities | −394 | −1,258 | −310 | −338 | −749 | |
| Proceeds from the issuance of common stock under employee stock plans | 72 | 77 | 67 | 58 | 55 | |
| Payment of taxes related to net share settlement of equity awards | −29 | −30 | −54 | −67 | −76 | |
| Payments for repurchase of common stock | −425 | −1,150 | −575 | −1,139 | −788 | |
| Payment of excise taxes related to repurchases of common stock | −10 | −3 | 0 | 0 | — | |
| Payment of dividends | −282 | −274 | −265 | −250 | −236 | |
| Proceeds from Issuance of Long-Term Debt | 4 | 1,197 | 0 | 600 | 848 | |
| Repayments of Long-Term Debt | −3 | −600 | 0 | −609 | 417 | |
| Payments of debt issuance costs | 0 | −9 | 0 | 0 | −7 | |
| Net proceeds from (Repayments of ) Short-Term Debt | −42 | 40 | −35 | 35 | −75 | |
| Payment for Contingent Consideration | 0 | 0 | −68 | 0 | 0 | |
| Net cash used in financing activities | −715 | −752 | −930 | −1,372 | −696 | |
| Effect of exchange rate movements | 9 | −2 | 5 | −36 | 3 | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 459 | −261 | 537 | −434 | 43 | |
| Income Taxes Payments, Net of refunds received | 318 | 314 | 199 | 279 | 211 | |
| Interest payments, net of capitalized interest | 101 | 80 | 89 | 85 | 76 | |
| Net change in property, plant and equipment included in accounts payable and accrued liabilities-increase (decrease) | 11 | 9 | 4 | 26 | 27 |